Protara Therapeutics, Inc. — Director's Dealing 2016

Oct 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2016-10-18

Reporting Person: HASTINGS PAUL J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-18	Stock Option (Right to Buy)	$9.00	A	13333	Acquired	2026-10-17	Common Stock, $0.001 par value (13333)	Direct

Footnotes

F1: The options were granted on October 18, 2016 and will vest annually over a three-year period measured from the date of grant.